Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: Results of CMG2002 trial

Leukemia and Lymphoma

Volumn 53, Issue 5, 2012, Pages 920-927

  Nemec, Pavel ^a   Zemanova, Zuzana ^b   Kuglik, Petr ^a,c   Michalova, Kyra ^b   Tajtlova, Jana ^b   Kaisarova, Petra ^a   Oltova, Alexandra ^c   Filkova, Hana ^a   Holzerova, Milena ^d   Balcarkova, Jana ^d   Jarosova, Marie ^d   Rabasova, Jana ^e   Hruba, Martina ^f   Spicka, Ivan ^b   Gregora, Evzen ^g   Adam, Zdenek ^c   Scudla, Vlastimil ^h   Maisnar, Vladimir ^e   Schutzova, Miroslava ^f   Hajek, Roman ^a,c  

^a MASARYK UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^d UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^e UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^f Faculty Hospital Plzen   (Czech Republic)

^g CHARLES UNIVERSITY   (Czech Republic)

^h PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

chromosomal abnormalities; cytogenetics and molecular genetics; Multiple myeloma; prognostic factors; stem cell transplantation

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CALCIUM; HEMOGLOBIN; IMMUNOGLOBULIN HEAVY CHAIN;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME 1Q; CHROMOSOME ABERRATION; CHROMOSOME LOSS; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; CYTOGENETICS; DIPLOIDY; DISEASE COURSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HIGH RISK PATIENT; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MONOSOMY; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; TREATMENT RESPONSE;

ADULT; AGED; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 4; CYTOGENETIC ANALYSIS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; KARYOTYPING; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; SURVIVAL RATE; TRANSLOCATION, GENETIC; TRANSPLANTATION, AUTOLOGOUS;

EID: 84859937530     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.634042     Document Type: Article

References (41)

1. Ludwig H, Durie BG, Bolejack V, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood 2008;111:4039-4047.
2. Fonseca R, Debes-Marun CS, Picken EB, et al. Th e recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 2003;102:2562-2567. (Pubitemid 37193596)
3. Smadja NV, Leroux D, Soulier J, et al. Further cytogenetic characterization of multiple myeloma confi rms that 14q32 translocations are a very rare event in hyperdiploid cases. Genes Chromosomes Cancer 2003;38:234-239. (Pubitemid 37259640)
4. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classifi cation of multiple myeloma. J Clin Oncol 2005;23:6333-6338. (Pubitemid 46218843)
5. Chng WJ, Santana-Davila R, Van Wier SA, et al. Prognostic factors for hyperdiploid-myeloma: eff ects of chromosome 13 deletions and IgH translocations. Leukemia 2006;20:807-813.
6. Carrasco DR, Tonon G, Huang Y, et al. High-resolution genomic profi les defi ne distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006;9:313-325.
7. Moreau P, Facon T, Leleu X, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002;100:1579-1583. (Pubitemid 34925131)
8. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007;109:3489-3495. (Pubitemid 46572539)
9. Gutierrez NC, Castellanos MV, Martin ML, et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 2007;21:143-150. (Pubitemid 44921845)
10. Chang H, Qi X, Trieu Y, et al. Multiple myeloma patients with CKS1B gene amplifi cation have a shorter progression-free survival post-autologous stem cell transplantation. Br J Haematol 2006;135:486-491. (Pubitemid 44583412)
11. Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fl uorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006;108:1724-1732. (Pubitemid 44316143)
12. Boyd KD, Ross FM, Tapper WJ, et al. Defi ning high risk myeloma using co-segregating FISH variables; results of MRC Myeloma IX. Blood 2010;116(Suppl. 1): Abstract 1907.
13. Hajek R, Spicka I, Scudla V, et al. Consolidation therapy based on conventional chemotherapy and corticoids do not provide therapeutic advantage for newly diagnosed patients after autologous transplantation. Blood 2007;110(Suppl. 1): Abstract 531.
14. Nemec P, Zemanova Z, Greslikova H, et al. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy. Biol Blood Marrow Transplant 2010;16:548-554.
15. Ross FM, Avet-Loiseau H, Drach J, et al.; on behalf of the European Myeloma Network FISH Working Party. European Myeloma Network recommendations for FISH in myeloma. Haematologica 2007;92(Suppl. 2):100-101.
16. Avet-Loiseau H, Leleu X, Roussel M, et al. Deletion of the 17p chromosomal region is associated with a very poor outcome in multiple myeloma independently of the type of treatment. Blood 2009;114:721-722.
17. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-1473. (Pubitemid 44264086)
18. Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003;101:4569-4575. (Pubitemid 36857829)
19. Neben K, Jauch A, Bertsch U, et al. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classifi cation allows stratifi cation of myeloma patients undergoing autologous stem cell transplantation. Haematologica 2010;95:1150-1157.
20. Greslikova H, Zaoralova R, Filkova H, et al. Negative prognostic signifi cance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation. Neoplasma 2010;57:111-117.
21. Shaughnessy J. Amplifi cation and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology 2005;10(Suppl. 1):117-126. (Pubitemid 41829514)
22. Fonseca R, Van Wier SA, Chng WJ, et al. Prognostic value of chromosome 1q21 gain by fl uorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia 2006;20:2034-2040. (Pubitemid 44614894)
23. Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defi ned by deregulated expression of genes mapping to chromosome 1. Blood 2007;109:2276-2284. (Pubitemid 46425864)
24. Keats JJ, Maxwell CA, Taylor BJ, et al. Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)- positive multiple myeloma patients. Blood 2005;105:4060-4069. (Pubitemid 40656156)
25. Santra M, Zhan F, Tian E, et al. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood 2003;101:2374-2376. (Pubitemid 36302083)
26. Fonseca R, Oken MM, Harrington D, et al. Deletions of chromosome 13 in multiple myeloma identifi ed by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia 2001;15:981-986. (Pubitemid 32529901)
27. Avet-Louseau H, Daviet A, Sauner S, et al. Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br J Haematol 2000;111:1116-1117. (Pubitemid 32104926)
28. Shaughnessy J, Tian E, Sawyer J, et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood 2000;96:1505-1511. (Pubitemid 30658483)
29. Zojer N, Konigsberg R, Ackermann J, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fl uorescence in situ hybridization. Blood 2000;95:1925-1930. (Pubitemid 30151627)
30. Chiecchio L, Protheroe RK, Ibrahim AH, et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia 2006;20:1610-1617. (Pubitemid 44264105)
31. Shaughnessy J Jr, Tian E, Sawyer J, et al. Prognostic impact of cytogenetic and interphase fl uorescence in situ hybridization-defi ned chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol 2003;120:44-52. (Pubitemid 36056907)
32. Drach J, Ackermann J, Fritz E, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 1998;92:802-809. (Pubitemid 28355463)
33. Xiong W, Wu X, Starnes S, et al. An analysis of the clinical and biologic signifi cance of TP53 loss and the identifi cation of potential novel transcriptional targets of TP53 in multiple myeloma. Blood 2008;112:4235-4246.
34. Chang H, Qi C, Yi QL, et al. p53 gene deletion detected by fl uorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 2005;105:358-360. (Pubitemid 40053104)
35. Reece D, Song KW, Fu T, et al. Infl uence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse eff ect of deletion 17p13. Blood 2009;114:522-525.
36. Gertz MA, Lacy MQ, Dispenzieri A, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005;106:2837-2840. (Pubitemid 41510761)
37. Kapoor P, Kumar S, Fonseca R, et al. Impact of risk stratifi cation on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2009;114:518-521.
38. Bahlis NJ, Mansoor A, Lategan JC, et al. Lenalidomide overcomes poor prognosis conferred by deletion of chromosome 13 and t(4;14) in multiple myeloma: MM016 trial. Blood 2006;108(Suppl. 1): Abstract 3557.
39. Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007;21:151-157. (Pubitemid 44921846)
40. Richardson PG, Barlogie B, Berenson J, et al. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 2005;106:2977-2981. (Pubitemid 41565888)
41. Sagaster V, Ludwig H, Kaufmann H, et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 2007;21:164-168. (Pubitemid 44921848)